NCT01111955 - Safety Study of BMS-823778 in Subjects With Type 2 Diabetes | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

BMS-823778

Capsules, Oral, 2 mg, once daily, 28 days

DRUG

BMS-823778

Capsules, Oral, 10 mg, once daily, 28 days

DRUG

BMS-823778

Capsules, Oral, 20 mg, once daily, 28 days

DRUG

Placebo

Capsules, Oral, 0 mg, once daily, 28 days

DRUG

Metformin

Capsules, Oral, ≥ 1500 mg, once daily, 28 days

Trial Locations (14)

2148

Local Institution, Blacktown

3128

Local Institution, Box Hill

6959

Local Institution, Freemantle

33012

Farid Marquez, Md, Hialeah

53209

Aurora Advanced Healthcare, Milwaukee

98502

Capital Clinical Reserch Center, Olympia

V4A 2H9

Local Institution, Surrey

R3E 3P4

Local Institution, Winnipeg

E2A 4X7

Local Institution, Bathurst

A1A 3R5

Local Institution, St. John's

L4J 8L7

Local Institution, Thornhill

J7J 2K8

Local Institution, Mirabel

G1N 4V3

Local Institution, Québec

S7K 7H9

Local Institution, Saskatoon